Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000805 · ClinicalTrials.gov registry record · Phase 4
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 528
- Enrollment target
NCT01000805 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 528 participants.
The verdict
NCT01000805, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 528 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than placebo when treating depression and its associated painful symptoms.
Interventions
- DRUG Placebo
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000805
The ClinicalTrials.gov registry entry for NCT01000805 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 528 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01000805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000805 about?
NCT01000805 is a clinical study titled "A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms". The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than placebo when treating depression and its associated painful symptoms.
What is the current status of trial NCT01000805?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 528 participants. The study started on 2009-11. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01000805?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG).
Who is sponsoring clinical trial NCT01000805?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.